[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334391-105":59,"doc-detail-334391-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","how-is-value-defined-in-molecular-testing-in-cancer-a-scoping-review","How is Value Defined in Molecular Testing in Cancer? - A Scoping Review","","Scoping review examines how studies define value for molecular testing in cancer and how far healthcare value frameworks have been broadened within this literature. The review follows Joanna Briggs Institute guidance, searching Medline, Embase, EconLit, and the Cochrane Library in August 2023. Included studies report costs linked to outcomes, novel costs, or novel outcomes. Results synthesise qualitative content analysis and conclude conventional economic measures dominate, while non-clinical value concepts remain uncommon.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/how-is-value-defined-in-molecular-testing-in-cancer-a-scoping-review/334391/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/how-is-value-defined-in-molecular-testing-in-cancer-a-scoping-review/334391.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the review investigate about molecular testing value in cancer?","Question",{"text":112,"@type":113},"It identifies how value is defined in studies focused on molecular testing in cancer and assesses the extent to which broader healthcare value concepts are applied in that literature.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were eligible studies selected for the scoping review?",{"text":117,"@type":113},"The review used Joanna Briggs Institute guidance and searched Medline, Embase, EconLit, and the Cochrane Library in August 2023. Studies were included if they reported costs relative to outcomes, novel costs, or novel outcomes of molecular testing in cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"What value measures dominate the included literature?",{"text":121,"@type":113},"Most included studies were conventional economic analyses, and clinical outcomes dominated value assessment. QALYs were the most common outcome measure.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334391,1790101318,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":4},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Applied Health Economics and Health Policy (2025) 23:409–424  \n[https://doi.org/10.1007/s40258-024-00901-4](https://doi.org/10.1007/s40258-024-00901-4)  \nHow is Value Defined in Molecular Testing in Cancer? A Scoping Review  \nAlice Minhinnick1 · Francisco Santos‑Gonzalez2 · Michelle Wilson1 · Paula Lorgelly1  \nAccepted: 18 June 2024 / Published online: 9 July 2024 © The Author(s) 2024  \nAbstract  \nObjective To identify how value is defined in studies that focus on the value of molecular testing in cancer and the extent to which broadening the conceptualisation of value in healthcare has been applied in the molecular testing literature. Methods A scoping review was undertaken using Joanna Briggs Institute (JBI) guidance. Medline, Embase, EconLit and Cochrane Library were searched in August 2023. Articles were eligible if they reported costs relative to outcomes, novel costs, or novel outcomes of molecular testing in cancer. Results were synthesised and qualitative content analysis was performed with deductive and inductive frameworks.  \nResults Ninety-one articles were included in the review. The majority (75/91) were conventional economic analyses (comparative economic evaluations and budget impact assessments) and undertaken from a healthcare system perspective (38/91) . Clinical outcomes dominate the assessment of value (61/91), with quality-adjusted life-years (QALYs) the most common outcome measure (45/91). Other definitions of value were diverse (e.g. psychological impact, access to trials), inconsistent, and largely not in keeping with evolving guidance.  \nConclusions Broader concepts of value were not commonly described in the molecular testing literature focusing on cancer. Conventional approaches to measuring the health costs and outcomes of molecular testing in cancer prevail with little focus on non-clinical elements of value. There are emerging reports of non-clinical outcomes of testing information, particularly psychological consequences. Intrinsic attributes of the testing process and preferences of those who receive testing information may determine the realised societal value of molecular testing and highlight challenges to implementing such a value framework.  \n1 Introduction  \nMolecular testing has a growing role in modern cancer care for diagnosing cancer, predicting responses to genetically targeted drugs, and estimating prognosis. With rapid advancement in the field of precision oncology, the presence of molecular testing in clinical guidelines and demand for molecular testing continues to rise [1, 2] . As is the case for all technological advances in health, it is vital to understand how, where, when and to whom molecular tests provide value for money (i.e. , in the economic sense, the necessary evidence base for the quantification of the incremental costs relative to the incremental outcomes) .  \n* Alice Minhinnick [alice.minhinnick@auckland.ac.nz](alice.minhinnick@auckland.ac.nz)  \n* Paula Lorgelly [Paula.Lorgelly@auckland.ac.nz](Paula.Lorgelly@auckland.ac.nz)  \n1 University of Auckland, Auckland, New Zealand  \n2 University of Melbourne, Melbourne, VIC, Australia  \nHealth technology assessment (HTA) across the technology life cycle [3]—from molecular testing research and development, regulatory approval, pricing and reimbursement, to optimal clinical implementation—requires robust, readily communicated evidence on value to ensure optimal and equitable patient care.  \nHowever, existing evidence available to decision-makers on the costs and outcomes of molecular testing in cancer is limited by methodological challenges, including the lack of an agreed definition for value [4] and inconsistent approaches to quantifying value [5–12] . Terkola's editorial [4] summarised the key challenge in economic evaluation in precision medicine: A lack of high-quality data on costs and health outcomes underscored by the lack of a consensus definition of value.  \nConventional approaches to measuring incremental costs and","cbCaiuJd9d0P8VO7","https://ap.wps.com/l/cbCaiuJd9d0P8VO7","pdf",1540496,16,"English","# Abstract\n# Introduction\n## Value in molecular testing\n# Key Points for Decision Makers","[{\"question\":\"What does the review investigate about molecular testing value in cancer?\",\"answer\":\"It identifies how value is defined in studies focused on molecular testing in cancer and assesses the extent to which broader healthcare value concepts are applied in that literature.\"},{\"question\":\"How were eligible studies selected for the scoping review?\",\"answer\":\"The review used Joanna Briggs Institute guidance and searched Medline, Embase, EconLit, and the Cochrane Library in August 2023. Studies were included if they reported costs relative to outcomes, novel costs, or novel outcomes of molecular testing in cancer.\"},{\"question\":\"What value measures dominate the included literature?\",\"answer\":\"Most included studies were conventional economic analyses, and clinical outcomes dominated value assessment. QALYs were the most common outcome measure.\"}]","How is Value Defined in Molecular Testing in Cancer? - A Scoping Review | PDF",1790006483]